（文章来源：证券时报网） 截至10月31日收盘，禽流感概念上涨3.32%，位居概念板块涨幅第6，板块内，24股上涨，众生药业、 联环药业等涨停，华兰疫苗、东方生物、ST香雪等涨幅居前，分别上涨17.88%、7.24%、6.41%。 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 600513 | 联环药 业 | 10.01 | 13.81 | 34865.65 | 41.17 | | 002317 | 众生药 业 | 10.02 | 10.14 | 30472.71 | 20.95 | | 301207 | 华兰疫 苗 | 17.88 | 3.99 | 6422.39 | 13.04 | | 300498 | 温氏股 份 | 0.55 | 0.59 | 5852.64 | 9.11 | | 300147 | ST香雪 | | 3.34 | 1985.21 | 9.03 | | 002603 | 以岭药 业 | 2.11 ...

Core Viewpoint - The avian influenza concept sector has seen a significant increase, with a rise of 2.45%, ranking third among concept sectors on the trading day ending August 19. Group 1: Sector Performance - The avian influenza sector had 18 stocks rising, with ST Xiangxue hitting a 20% limit up, and Kangyuan Pharmaceutical also reaching the limit up. Other notable gainers included Yongshun Biological, Lianhuan Pharmaceutical, and Zhongsheng Pharmaceutical, which rose by 9.35%, 6.08%, and 3.79% respectively [1] - The top-performing concept sectors included: - Reducer: +2.62% - Animal Vaccine: +2.47% - Avian Influenza: +2.45% [1] Group 2: Capital Flow - The avian influenza sector attracted a net inflow of 109 million yuan, with 15 stocks receiving net inflows. Five stocks had net inflows exceeding 10 million yuan, led by Kangyuan Pharmaceutical with a net inflow of 154 million yuan [1] - The top stocks by net capital inflow ratio included: - Kangyuan Pharmaceutical: 19.87% - ST Xiangxue: 14.18% - Zhongmu Stock: 5.23% [2]

Core Insights - The avian influenza concept sector saw an increase of 1.62%, ranking fourth among concept sectors in terms of growth, with 20 stocks rising, including Zhongsheng Pharmaceutical, Lianhuan Pharmaceutical, and Yongshun Biological, which rose by 7.49%, 7.31%, and 6.32% respectively [1] - The sector experienced a net inflow of 938 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 30 million yuan, led by Zhongsheng Pharmaceutical with a net inflow of 533 million yuan [1] Sector Performance - The top-performing concept sectors included: - Animal vaccines: +2.22% - DRG/DIP: +1.87% - BC batteries: +1.71% - Avian influenza: +1.62% - Medical waste treatment: +1.61% [1] Fund Flow Analysis - Leading stocks in terms of fund inflow ratios included: - Lianhuan Pharmaceutical: 21.80% - Zhongsheng Pharmaceutical: 15.06% - Taiji Group: 9.94% [2] - The top stocks by main fund flow included: - Zhongsheng Pharmaceutical: 532.84 million yuan - Lianhuan Pharmaceutical: 278.91 million yuan - Taiji Group: 97.84 million yuan [2][3]

Group 1 - The core viewpoint of the news is that the avian influenza concept sector has seen a significant increase, ranking fourth among concept sectors with a rise of 2.33% as of the market close on July 16 [1][2]. - Within the avian influenza sector, 24 stocks experienced gains, with notable performers including Biological Shares and Lianhuan Pharmaceutical, which hit the daily limit, and others like Ruipu Biological and Zhongmu Shares, which rose by 5.65%, 3.70%, and 3.56% respectively [1][2]. - The avian influenza concept sector attracted a net inflow of 301 million yuan from main funds today, with 12 stocks receiving net inflows, and 6 stocks seeing inflows exceeding 10 million yuan [2][3]. Group 2 - The leading stocks in terms of net fund inflow within the avian influenza concept include Biological Shares with a net inflow of 159 million yuan, followed by Lianhuan Pharmaceutical and Zhongsheng Pharmaceutical with inflows of 95.22 million yuan and 70.42 million yuan respectively [2][3]. - The net inflow ratios for the top stocks are as follows: Biological Shares at 19.39%, Lianhuan Pharmaceutical at 11.66%, and Zhongsheng Pharmaceutical at 5.64% [3][4]. - The trading volume and turnover rates for the leading stocks in the avian influenza sector indicate strong investor interest, with Biological Shares showing a turnover rate of 8.74% and Lianhuan Pharmaceutical at 18.86% [3][4].